๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Androgen suppression therapy and prostate cancer : Balancing the harms and the benefits

โœ Scribed by Michael G. Oefelein

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
60 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

Men with localized, lowโ€risk carcinoma of the prostate with multiple comorbidities may experience few benefits from androgen suppression therapy (AST), and probably would be better served by an active surveillance approach, with delayed AST if evidence of progression develops. A proactive position regarding the potential for AST to unmask existing or occult coronary artery disease or for AST to facilitate development of cardiovascular disease warrants consideration.

๐Ÿ“œ SIMILAR VOLUMES

Reply to balancing the harms and benefit
Reply to balancing the harms and benefits of early detection of prostate cancer
โœ Pim J. van Leeuwen; David Connolly ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 100 KB ๐Ÿ‘ 1 views

## Results of a Prospective Phase 2 Trial With great interest we read the article by Brown et al, who reported the results of a phase 2 study using gemcitabine and cisplatin in patients with advanced endometrial cancer. 1 Although we recognize the reported impressive activity of this regimen, we b

Influence of body mass index on prostate
Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer
โœ Jason A. Efstathiou; Ming-Hui Chen; Andrew A. Renshaw; Marian J. Loffredo; Antho ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 112 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Increasing body mass index (BMI) is associated with shorter time to prostateโ€specific antigen (PSA) failure after radical prostatectomy. Whether BMI is associated with time to PSA failure was investigated in men treated with androgen suppression therapy (AST) and radiatio

Time to an undetectable prostate-specifi
Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
โœ Anthony V. D'Amico; David G. McLeod; Peter R. Carroll; Jennifer Cullen; Ming-Hui ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 172 KB

## Abstract ## BACKGROUND For men receiving androgenโ€suppression therapy (AST) for a rising postoperative or postradiation prostateโ€specific antigen (PSA) recurrence, whether the time to an undetectable (u) PSA was significantly associated with prostate cancerโ€specific mortality (PCSM) was evaluat